comparemela.com

Latest Breaking News On - Pertuzumab - Page 1 : comparemela.com

Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.

Antonio llombart cussacUniversity hospital arnau de vilanovaOncology serviceMedical oncology serviceHer2 positive early breast cancerChemotherapy free regimen

NRG-GY018 and RUBY Trials in Endometrial Cancer

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

Ramez eskanderMatthewa powellUrsulaa matulonisBhavana pothuriShannonn westinEndometrial cancerRuby trialAsco 2023Nrg gy018Sgo 2023Mismatch repair

Ongoing Research in HER2+ Metastatic Breast Cancer

An overview of agents and treatment strategies currently being investigated in HER2+ metastatic breast cancer.

Megan kruseHer2 metastatic breast cancerPrecious trialT dm1Overall survivalAsco 2023Her2 targeted therapyLeptomeningeal disease

Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

Improving outcomesBreast cancerTranslating evidenceClinical practiceYear old woman withMetastatic breast cancerVirginia kaklamaniHer2 positiveHer2 breast cancerInterstitial lung diseaseThp therapyCleopatra trialCleopatra regimenCleopatra studyTrastuzumab deruxtecanT dxd

Overview of the HER2+ Metastatic Breast Cancer Treatment Armamentarium

A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.

Improving outcomesBreast cancerTranslating evidenceClinical practiceMetastatic breast cancer treatmentMetastatic breast cancerHer2 positiveHer2 breast cancerThp therapyCleopatra regimenTrastuzumab emtansineDestiny breast03Trastuzumab deruxtecanT dxdDestiny breast02Her2climb trial

vimarsana © 2020. All Rights Reserved.